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Abstract. 
Dose volume histograms are a useful tool in state-of-the-art radiotherapy planning, and it is 
essential to be aware of their limitations. Dose distributions computed by treatment planning 
systems are affected by several sources of uncertainty such as algorithm limitations, measurement 
uncertainty in the data used to model the beam and residual differences between measured and 
computed dose, once the model is optimized. In order to take into account the effect of uncertainty, 
a probabilistic approach is proposed and a new kind of histogram, a dose-expected volume 
histogram, is introduced. The expected value of the volume in the region of interest receiving an 
absorbed dose equal or greater than a certain value is found using the probability distribution of the 
dose at each point. A rectangular probability distribution is assumed for this point dose, and a 
relationship is given for practical computations. This method is applied to a set of dose volume 
histograms for different regions of interest for 6 brain patients, 8 lung patients, 8 pelvis patients and 
6 prostate patients planned for IMRT. These results show how dose computation uncertainty has 
effects on PTV coverage and, to a lesser extent, in dose to organs at risk. This method allows to 
quantify these effects. 
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Introduction. 
Dose volume histograms (DVH) were introduced as a tool for plan evaluation in the late 80s, at a 
time when three dimensional dose computations were becoming state-of-the-art
1
. Dose volume 
histograms started being used routinely for plan evaluation and even dose prescription very soon. 
Currently, dose volume histogram constraints are used as input data for intensity modulated 
radiation therapy (IMRT) planning. Actually, prescription based on DVHs has replaced the 
traditional dose to a point approach when prescribing and reporting IMRT treatments, because of 
the impossibility of fulfilling ICRU requirements
2,3
. Thus, a careful study on accuracy of dose 
volume histogram computation is now as necessary as for point dose calculations, and most recent 
reports on treatment planning quality assurance make recommendations about DVH accuracy 
assessment
4,5,6,7,8,9,10
.  
 
Despite these efforts, a statement of uncertainty for a particular DVH value is not as 
straightforward, as it is with point dose. Since a DVH is a statistical concept, its value for a 
particular dose level is obtained from many point dose computations, and their uncertainties are not 
correlated.  
 
Niemierko and Goitein
11
, and Lu and Chin
12
 published work on DVH computation accuracy, 
comparing two methods of volume computation: random (or quasi random) sampling and grid 
placement. Advantages and disadvantages of both methods were the subject of further 
comments
13,14
. Kooy et al
15
 published a new methodology for volume assessment in small, nearly 
spherical volumes of interest, adapted for its use in radiosurgery plans, which improved volume 
computation accuracy. The issue of dose uncertainty in DVHs was not addressed in these papers. 
 Uncertainties for point dose computations arise from several different sources. There is an inherent 
random (type A) measurement uncertainty in the data used for modeling the beams; there is a type 
B uncertainty due to algorithm limitations, which depends on patient and organ features (geometry 
and tissue density) and beam characteristics; and there is also a type B uncertainty due to imperfect 
matching between measured and computed data when modeling the beam. When specifying dose to 
a point, a composition of uncertainties from all sources must be used. The problem of combining 
these uncertainties to obtain the uncertainty of a dose volume histogram value is complex. Different 
voxels with the same computed absorbed dose can have very different irradiation conditions, and 
they depend on the beam arrangement and patient anatomy. A probabilistic approach has been 
chosen in this paper. A modified version of the DVH has been developed, which takes into account 
the probability of each voxel receiving a dose greater than the dose level considered.  
 
Some applications to clinical plans have been prepared to illustrate the effects of dose uncertainty 
on DVHs, and a summary of statistical parameters is provided as a result. 
 
Materials and Methods. 
 
Theory. The standard definition of cumulative dose volume histogram, DVHc(x), of a region of 
interest (ROI) at dose level x is: the volume contained in the region of interest receiving a dose 
equal or greater than x
1
. It is common practice to use relative volumes and/or doses, referring 
volumes to the ROI total volume and doses to an arbitrary chosen level (prescription dose). Another 
variant of this concept is the differential dose volume histogram, DVHd(x), which is defined as the 
volume contained in the region of interest receiving a dose level x. Relationships between both 
functions can be obtained easily. 
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Dose-volume histograms are usually computed for a discreet set of dose intervals of uniform length. 
Random sampling or regular grids are possible methods to sample dose points inside the region of 
interest. In practice, dose-volume histograms are computed on a discreet set of  voxels with 
volume vi, where the computed dose is assumed to be approximately constant and equal to the dose 
at a representative point zi (its centre). 
 
Because of uncertainty, absorbed dose at sample point zi can be represented mathematically as a 
random variable ∆i, with density function fi(δi), whose mean is D(zi) (computed dose in zi), and its 
variance σi
2
. The knowledge about this dose distribution is usually its variance or standard 
deviation. Standard deviations are the recommended parameter to evaluate uncertainties, because in 
this way uncertainties from different sources can be combined according to certain rules
16,17,18
, 
regardless of the particular distribution of probability. 
 
We are interested in evaluating probabilities for this random variable ∆i. Depending on the sort of 
dose uncertainty, and whether it is a type A or type B uncertainty, different probability density 
functions could be assumed. If there is a dominant type A component, due to experimental 
uncertainty, or to a composition of many small uncertainty sources, then the Central Limit Theorem 
may be applicable and a Gaussian distribution can be used. 
2
2
))((
2
1
)( i
ii zD
i
ii ef
σ
δ
σπ
δ
−
−
=  
In other situations, there is no information about which the probability distribution for our random 
variable is, and a rectangular density function is assumed, giving equal probability to any result 
within an upper and a lower bound (ISO Guide
16
). 
 
Regardless of the choice, it is assumed that the standard deviation is a constant percentage of the 
computed dose, i.e., relative uncertainty is constant within the region of interest R, so )(yDuy ⋅=σ  
(see below). We can then define a density function f(w) verifying 
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and f(w) has mean 0 and standard deviation 1.  
 
Cumulative dose-expected volume histogram, DeVHc(x), for the region of interest R and dose level 
x is defined as the expected value of the volume contained in R receiving a dose equal or greater 
than x.  
 
If xiT is defined as a random variable with value 1 when xi ≥δ  and 0 otherwise, then the sum 
∑
=
⋅

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x
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1
is a random variable corresponding to the volume receiving a dose greater than x. Each 
voxel adds the value vi to this summation according to 
x
iT . The dose expected volume histogram is 
obtained as the expectation value of this sum: 
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equation for DeVHc(x): 
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Each voxel in the region of interest R is weighted according to the probability tail to the right side 
of x. Each term in the summation depends on zi through D(zi). Thus, adding up all voxels with 
computed dose between dj and dj+1, corresponding to the j-eth dose bin, the final equation for 
DeVHc(dj) is 
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We have used the fact that the sum of all vi corresponding to voxels with computed dose between dk 
and dk+1 is DVHd(dk). There is a finite number of terms in the summation, because there is a 
maximum dose. 
 
This equation is consistent with the usual DVH definition. If a Dirac delta is used as probability 
distribution (no dose uncertainty), then F(w) is the Heavyside step function at 0. 
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is obtained. 
 
Now that DeVHc has been obtained as a summation in dose, it is possible to take into account 
differences in relative dose uncertainty throughout the region of interest, and relax the assumption 
made above. Accuracy of dose computation in low dose, low gradient regions is considered worse 
than in points inside the beam
19,20
. This fact could be partially taken into account by splitting the 
summation in different parts, using different u values for each range of computed doses. This 
approach has not been used in this paper, and a single value is used for u, which is the uncertainty 
for high dose points. Its use can only underestimate the effect of uncertainty. 
 
An upper bound for the uncertainty in DeVHc values can be obtained adding variances of 
x
iT . These 
random variables have correlation: errors arising from algorithm limitations in adjacent voxels, for 
instance, are likely to be similar, although this correlation is lost for distant voxels. Thus, 
uncertainty should be less than the value obtained from the sum of squares because of correlation 
terms. 
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At this point, a choice has to be made about the distribution associated to point dose computations. 
Having a non negligible Type B component arising from algorithm inaccuracy and limitations in 
beam modeling a rectangular distribution is the recommended option according to ISO
16
. Its density 
function (with mean 0 and variance 1) is 
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Let us derive DeVHc for this case. 
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And the dose expected volume histogram is 
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It is worth comparing this equation with the following one, 
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It can be observed that there is a redistribution of dose bins contributing to the value at level dj in 
the cumulative dose expected volume histogram. A certain amount of volume is now added from 
bins below dj, which did not contribute for DVHc(dj), and some volume is removed from higher 
dose bins, being the dose bins involved in this rearrangement the ones in the interval
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Figure 1 helps to illustrate this rearrangement. 
 
The uncertainty (standard deviation) of DeVHc(x) is 
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Larger differences between DeVH(dj) and DVH(dj) can be expected when the differential dose 
volume histogram has large values at and around dj. In other words, the worst case scenario would 
occur when the cumulative dose volume histogram is rapidly decreasing at dj. Obviously, a large 
uncertainty value gives also larger differences. 
 
Practical application. Equation 2 has been used to obtain dose-expected volume histograms for a 
set of plans and regions of interest: eight standard and six IMRT prostate plans for PTV, rectum and 
bladder; eight lung plans for PTV, both lungs and spinal cord; six brain plans for PTV and brain 
stem. Every plan has been the result of standard planning procedures in our institution. The 
treatment planning system used is Pinnacle v7.6g (Philips. Milpitas. CA). DVH dose bins were 25 
to 32 cGy wide, which means that there were around 200 points in each histogram. Dose and 
volume have always been used in absolute values (in cGy and cm
3
). 
 
A 3.6% value of uncertainty has been considered for every region of interest. This choice is based 
on the results given for Pinnacle by Venselaar and Welleweerd
21
 in their survey of treatment 
planning systems in the Netherlands. The confidence level for the “irregular block case” studied by 
them has been chosen, because MLC shaped beams have been used in every patient. This 
confidence level is 3.3% for Pinnacle. IAEA TRS-398
22
 provides a standard uncertainty value of 
1.5% (IAEA) for absolute dose determination in reference conditions. Both values are standard 
deviations and its composition gives the value 3.6 % that has been used in this paper. This value is 
an underestimation, because tests in this survey are still ideal situations where only one feature is 
taken into account at a time, and the IAEA value applies only to reference conditions. The same 
authors propose higher tolerance levels for combinations of irregular beams, in inhomogeneous 
media, in other publication
20
, and they can be used as an alternative. Different planning systems or 
different kind of treatments could lead to other figures for the uncertainty. 
 
For every region of interest several parameters were computed from their corresponding DVHs and 
DeVHs: mean dose, standard deviation, maximum dose (defined as the dose corresponding to 1 cm
3
 
in a cumulative histogram), minimum dose, median, first and third quartile. The differences in these 
parameters between DVHs and DeVHs are given as quantitative results. Some DVH values are 
studied also, and their value with uncertainty is computed from DeVH. A number of dose-volume 
parameters has been proved to have predictive value for certain side effects, according to the 
literature
23,24,25,26,27
: V20 and V30 for lungs, V65 for bladder, V60 or V72 for rectum in IMRT 
prostate treatments. Special fractionation schemes for prostate treatments have been developed in 
our institution, being the standard for conventional conformal radiotherapy 50 Gy in 16 fractions in 
22 days
28
, and a simultaneous boost technique for IMRT treatments with 54 Gy (PTV1), 57 Gy 
(PTV2) and 60 Gy (PTV3) in 3 Gy fractions
29
. As examples of application of DeVHs, values for 
V40 for bladder and rectum in conventional prostate treatments are given, and V50 in IMRT 
treatments. V50 for brain stem in brain treatments and V30 for lung are also studied as examples. 
The volume of the 95% isodose, a coverage descriptor for PTVs, has also been obtained. These 
magnitudes are shown as possible applications of DeVHs and do not reflect current practice in our 
department. 
 
Results and discussion 
 
Figure 2 illustrates what the impact of uncertainty in DeVH is. Several values of uncertainty have 
been used. We can see that the effect is more remarkable when the DVH gradient is higher. Thus, 
PTVs are more sensitive to uncertainty than large volume organs at risk like lungs. Figures 3-5 
show a comparison of DVHs and DeVHs, for several organs. It shows what the effect is depending 
on the organ that is being considered. A common feature in all DeVHs is the increase in maximum 
dose. 
 
Tables 1-4 show the differences in each of the parameters between DeVH and DVH for each region 
of interest for each of the treatments studied. Although the effect in mean dose is limited, maximum 
and minimum doses are further from these mean doses, making the dose distribution more 
inhomogeneous. The same feature is apparent when considering median dose and first and third 
quartiles.  
 
Table 5 shows values of V30, V40, V50, V65, V60, V95 depending on the region of interest, 
computed with DVH and DeVH, and its uncertainty in the latter case. V95 is shown as percentage 
of the prescribed dose. It can be seen that the 95% isodose has a lower volume if uncertainty is 
taken into account. The plan should be corrected if tumour coverage is to be insured despite 
uncertainty.  
 
Conclusions. 
 
Absorbed dose measurements and computations have some degree of uncertainty due to multiple 
causes. The figure of 5% (expanded uncertainty equivalent to twice a standard uncertainty) given in 
ICRU Report No. 24
30
 is often quoted as the goal for radiotherapy delivery needed to ensure tumour 
eradication. It is also widely recognized that this is a difficult goal to achieve, and that, although 
commercial computation algorithms are improving, treatment planning systems contribute to this 
overall uncertainty.  
 
Dose expected volume histograms are a useful tool when uncertainty has to be taken into account 
for decision making. Results show that dose homogeneity could not be as good as the treatment 
planning system shows for PTVs, and, if maximum dose is a concern, it is higher than the value 
given by the treatment planning system. If a goal has to be achieved safely, some margin for 
uncertainty has to be considered. 
 
We are used to attach an uncertainty estimation to point dose computations, for instance, ICRU-50 
point dose values. But measurement and computation uncertainty has effect on every point in our 
patient, and can compromise PTV coverage. The difference between conventional DVHs and 
DeVHs shows how large this influence can be. Dose expected volume histograms are a suitable tool 
for taking these effects into account, and their implementation into routine practice is easy. Users 
can make their own choices as to what probability distribution has to be used, how large the dose 
uncertainty is in their case, and what conclusions, or actions, can be reached. This way, it becomes 
possible to report external beam radiotherapy with a description of uncertainty, either when 
prescription is based on dose to a point or when it is based on dose volume relationships. 
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FIGURES. 
Figure 1. Contribution of the different dose bins to DeVH(dj). For each dose bin the rectangular 
probability distribution is shown, with the area contributing to DeVH(dj) in grey color. The sum of 
the grey areas, weighted by the differential DVH, equals DeVH(dj).  
 
Figure 2. DVH and DeVH for the PTV of an IMRT prostated plan. Five DeVH have been 
superimposed, with different dose uncertainty values: 1%, 2%, 3%, 4%, 5%. 
 
Figure 3. DVH and DeVH (with u=3.6%) for a prostate treatment planned with step and shoot 
IMRT. a) PTV, b) Bladder, c) Rectum. 
 
Figure 4. DVH and DeVH (with u=3.6%) for a lung treatment. a) PTV, b) Spinal cord, c) Left lung. 
 
Figure 5. DVH and DeVH (with u=3.6%) for a brain treatment. a) PTV, b) Brain stem. 
 
 Table 1. Mean dose, standard deviation, maximum dose, minimum dose, median dose, first and 
third quartiles computed with DeVH and DVH for conventional prostate plans. The values shown 
are the ones for the case with largest differences for each region of interest. All values in the table 
are in cGy.  
Prostate 
PTV Bladder Rectum 
DVH DeVH DVH DeVH DVH DeVH 
Mean Dose 4919.7 4907.12 4271.5 4258.9 3681.4 3668.8 
Standard deviation 2.9 11.9 55.6 56.5 56.3 57.0 
Maximum Dose 4987.5 5261.4 4968.9 5214.9 4919.5 5103.7 
Minimum Dose 4725.0 4425.0 2600.0 2425.0 2725.0 2550.0 
Median Dose 4940.7 4919.3 4826.3 4683.1 3461.5 3451.0 
First quartile 4908.4 4765.9 3510.3 3489.8 2811.1 2844.5 
Third quartile 4964.9 5072.7 4935.2 4932.9 4664.6 4590.8 
 
Table 2. Mean dose, standard deviation, maximum dose, minimum dose, median dose, first and 
third quartiles computed with DeVH and DVH for IMRT prostate plans. The values shown are the 
ones for the case with largest differences for each region of interest. All values in the table are in 
cGy.  
Prostate IMRT 
PTV1 PTV2 PTV3 Bladder Rectum 
DVH DeVH DVH DeVH DVH DeVH DVH DeVH DVH DeVH 
Mean Dose 6912.7 6893.7 7175.2 7156.1 7338.1 7319.0 5136.5 5117.5 4925.2 4906.2 
Standard deviation 27.4 31.9 
 
15.0 22.6 9.3 19.6 99.6 100.4 92.9 93.7 
Maximum Dose 7600.0 8056.0 7600.0 8056.0 7600.0 8056.0 7600.0 8056.0 7334.0 7790.0 
Minimum Dose 5320.0 5016.0 6384.0 5966.0 6954.0 6498.0 1254.0 1140.0 684.0 608.0 
Median Dose 6998.0 6932.6 7203.8 7170.1 7375.6 7335.2 5232.8 5204.0 4824.0 4817.4 
First quartile 6597.0 6567.1 7028.5 6927.5 7245.9 7106.5 3751.6 3758.4 4135.2 4118.5 
Third quartile 7277.1 7275.7 7384.5 7426.4 7479.3 7569.4 6613.0 6520.1 6183.5 6143.5 
 
Table 3. Mean dose, standard deviation, maximum dose, minimum dose, median dose, first and 
third quartiles computed with DeVH and DVH for lung plans. The values shown are the ones for 
the case with largest differences for each region of interest. All values in the table are in cGy.  
Lung 
PTV Spinal Cord Left Lung Right Lung 
DVH DeVH DVH DeVH DVH DeVH DVH DeVH 
Mean Dose 5414.4 5399.7 822.3 823.4 406.7 394.5 2238.9 2225.4 
Standard deviation 10.3 16.4 51.3 51.3 30.4 30.5 126.7 126.9 
Maximum Dose 5830.7 6182.3 2402.6 2549.1 1699.4 1787.3 5830.7 6182.3 
Minimum Dose 4336.4 4043.4 0.0 0.0 0.0 0.0 0.0 0.0 
Median Dose 5428.2 5413.4 347.0 344.9 129.3 116.4 1921.6 1908.1 
First quartile 5340.9 5232.1 153.0 152.2 69.1 55.1 308.5 294.6 
Third quartile 5528.2 5596.6 1733.7 1720.0 950.7 931.1 3736.6 3750.7 
 
Table 4. Mean dose, standard deviation, maximum dose, minimum dose, median dose, first and 
third quartiles computed with DeVH and DVH for brain plans. The values shown are the ones for 
the case with largest differences for each region of interest. All values in the table are in cGy.  
Brain 
PTV Brain stem 
DVH DeVH DVH DeVH 
Mean Dose 6009.7 5994.2 2573.5 2558.0 
Standard deviation 7.9 16.2 76.6 76.9 
Maximum Dose 6231.0 6603.0 5580.0 5921.0 
Minimum Dose 3658.0 3410.0 279.0 248.0 
Median Dose 6035.8 6012.6 2418.7 2408.3 
First quartile 5993.1 5822.4 2002.5 1976.2 
Third quartile 6091.5 6207.1 3576.4 3544.4 
 
Table 5. Values for different parameters computed from DVH and DeVH. For each parameter, 
values are shown for the patients for which DVH and DeVH give the largest and the smallest 
difference. 
Region of interest 
Minimum difference case Maximum difference case 
DVH DeVH DVH DeVH 
Prostate 
PTV V95 (%) 99.95 81.1 ± 3.0 99.8 72.9 ± 3.5 
Bladder V40 (cm3) 34.95 34.91 ± 0.59  46.8 45.3 ± 1.2 
Rectum V40 (cm3) 19.47 19.30 ± 0.88 23.61 23.42 ± 0.94 
Prostate IMRT 
PTV V95 (%) 100.0 88.9 ± 2.6 99.6 80.6 ± 3.2 
Bladder V50 (cm3) 32.8 32.2 ± 1.5 26.0 24.2 ± 1.8 
Rectum V50 (cm3) 25.3 25.2 ± 1.2 27.6 26.7 ± 1.7 
Lung 
PTV V95 (%) 96.3 79.4 ± 2.3 88.0 82.0 ± 1.1 
Left lung V30 (cm3) 61.00 61.3 ± 2.7 330.5 328.6 ± 2.5 
Right lung V30 (cm3) 182.6 179.8 ± 3.1 1102.82 1094.23 ± 4.5 
Brain 
PTV V95 (%) 97.7 90.0 ± 5.6 99.9 83.2 ± 3.0 
Brain stem V50(cm3) 0.27 0.28 ± 0.09 9.5 9.3 ± 1.3 
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